TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics TGTX, revealing diverse outlooks from ...

TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

Most readers would already be aware that TG Therapeutics' (NASDAQ:TGTX) stock increased significantly by 49% over the past three months. Since the market usually pay for a company’s long-term ...

To report any concerns or inaccuracies, please contact us at [email protected]. The post TGTX Stock Earnings: TG Therapeutics Beats EPS, Beats Revenue for Q2 2024 appeared first on ...

TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $23.19 which represents a slight increase of $0.12 or 0.52% from the prior close of $23.07. The stock opened at $22 ...

It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases. Latest Biotechnology & Medical Research and TG Therapeutics Inc, Intellia Therapeutics Inc Stock News As ...

(RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The company said the data ...

During the last three months, 4 analysts shared their evaluations of TG Therapeutics (NASDAQ:TGTX), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ...